← Back
$VRTX All transactions

VERTEX PHARMACEUTICALS INC / MA

▼ SELL 10b5-1 Plan

$ Value

$1.7M

Shares

3,498

Price

$494

Filed

Mar 3

Insider

Name

Kewalramani Reshma

Title

CEO & President

CIK

0001735944

Roles

Director Officer

Transaction Details

Transaction Date

2026-02-27

Code

S

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

121,578

Footnotes

Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025. | Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. | Open market sales reported on this line occurred at a weighted average price of $479.75 (range $479.75 to $479.76). | Open market sales reported on this line occurred at a weighted average price of $481.50 (range $481.50 to $481.51). | Open market sales reported on this line occurred at a weighted average price of $482.84 (range $482.84 to $482.85). | Open market sales reported on this line occurred at a weighted average price of $487.13 (range $486.64 to $487.55). | Open market sales reported on this line occurred at a weighted average price of $488.27 (range $487.82 to $488.56). | Open market sales reported on this line occurred at a weighted average price of $489.32 (range $489.01 to $489.79). | Open market sales reported on this line occurred at a weighted average price of $490.54 (range $490.10 to $491.01). | Open market sales reported on this line occurred at a weighted average price of $491.30 (range $491.13 to $491.85). | Open market sales reported on this line occurred at a weighted average price of $493.29 (range $492.78 to $493.77). | Open market sales reported on this line occurred at a weighted average price of $494.33 (range $493.78 to $494.75). | Open market sales reported on this line occurred at a weighted average price of $495.38 (range $494.79 to $495.78). | Open market sales reported on this line occurred at a weighted average price of $496.16 (range $495.79 to $496.74). | Open market sales reported on this line occurred at a weighted average price of $496.95 (range $496.79 to $497.17).

Filing Info

Accession No.

0000875320-26-000129

Form Type

4

Issuer CIK

0000875320

Kewalramani Reshma's History

Date Ticker Type Value
2026-02-27 VRTX $192K
2026-02-27 VRTX $58K
2026-02-27 VRTX $116K
2026-02-27 VRTX $1.2M
2026-02-27 VRTX $1.6M
2026-02-27 VRTX $225K
2026-02-27 VRTX $1.3M
2026-02-27 VRTX $466K
2026-02-27 VRTX $1.2M
2026-02-27 VRTX $1.7M

Other Insiders at VRTX (90d)

Insider Bought Sold Last
SACHS BRUCE I 2026-04-15
WAGNER CHARLES F JR
EVP, CO & FO
2026-02-24
LEIDEN JEFFREY M
Executive Chairman
2026-02-24
Garber Alan M 2026-04-15
Sachdev Amit
EVP Chief Patient & Ext Af Off
$28.4M 2026-02-25
Upadhyay Suketu 2026-04-15
ALTSHULER DAVID
EVP, Chief Scientific Officer
2026-01-22
Bhatia Sangeeta N. $133K 2026-02-13
Kewalramani Reshma
CEO & President
$18.0M 2026-02-27
Biller Jonathan
EVP and Chief Legal Officer
$3.6M 2026-02-25
Tatsis Ourania
EVP, Chief Reg. & Quality Off.
$1.6M 2026-02-25
Bozic Carmen
EVP and CMO
$3.3M 2026-03-27
Liu Joy
EVP and Chief Legal Officer
$882K 2026-04-01
Ambrose Kristen
SVP & Chief Accounting Officer
$2.0M 2026-02-26
Atkinson Edward Morrow III
EVP, Chief Technical Ops. Off.
$2.5M 2026-02-25
McKechnie Duncan
EVP, Chief Commercial Officer
$4.9M 2026-03-11
Bunnage Mark E.
EVP, Chief Scientific Officer
$3.0M 2026-02-25